Hohl Benjamin reported option exercise involving 3,982 shares of Enliven Therapeutics, Inc. at $14.85 for $59.1k on Sep 17, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CHIEF FINANCIAL OFFICER
CHIEF FINANCIAL OFFICER
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$59,132.70Shares × reported price
Shares traded
3,982Common Stock
Price per share
$14.85Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
44,018Direct
Trade date
Sep 17, 2026Option exercise
Filed
Sep 21, 2026, 5:23 PM ET4-day reporting delay
Accession
0001882764-26-000008Code M · Transaction 226950
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 17, 2026Option exercise3,982$0.00$0Trade 226954
Sep 17, 2026Sell3,535$50.03−$176,851.10Trade 226951
Sep 17, 2026Sell2,194$50.72−$111,270.47Trade 226952
Sep 17, 2026Sell289$51.49−$14,881.45Trade 226953
5 transaction rows in this filing. Joint filers share the same rows.

ELVN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ELVN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +20%1w ago +12%1d ago −2.2%
Returns since7d −8.4%30d −17%90d180d1y

Footnotes in full

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F3: This transaction was executed in multiple trades at prices ranging from $49.31 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4: This transaction was executed in multiple trades at prices ranging from $50.31 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6: The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, and the remainder of the shares vest in 36 equal monthly installments thereafter.